APRIL 2015 # 07

Upfront In My View Business Sitting Down With Cutting the cost of Bacteriophages: the answer to Fight for your (intellectual Dirk Sauer, Novartis’ Global antibody manufacture antibiotic resistance? property) rights! Head of Ophthalmics

10 18 44 – 46 50 – 51 Who’s Who on the Cover? In no particular order. Turn to page 23 for The Power List 2015 1 Parrish Galliher 21 Keith Williams 41 Richard Bergstrom 61 Ian Read 81 Dalvir Gill 2 Mark Offerhaus 22 Chris Frampton 42 Jens H. Vogel 62 Meindert Danhof 82 A. Seidel-Morgenstern 3 Shinya Yamanaka 23 Rino Rappuoli 43 Kenneth Frazier 63 John Aunins 83 David Pyott 4 Tyler Jacks 24 Robert Hugin 44 Peter Seeberger 64 Marijn Dekkers 84 Dennis Fenton 5 Olivier Brandicourt 25 Robert Bradway 45 Julie O’Neill 65 Marshall Crew 85 Barry Buckland 6 Robert Langer 26 Robin Robinson 46 Brian Overstreet 66 Joseph Schlessinger 86 Abbe Steel 7 Carsten Brockmeyer 27 Raman Singh 47 Claus-Michael Lehr 67 Alan Armstrong 87 Andreas Koester 8 Louis Monti 28 Mark Fishman 48 J. Craig Venter 68 George Scangos 88 Lamberto Andreotti 9 Kary Mullis 29 Lars Rebien Sørensen 49 John Chiminski 69 David Baltimore 89 Lisa Anson 10 Archie Lovatt 30 Marco Taglietti 50 J. Michael Wallace 70 Charles Cooney 90 William Chin 11 Yoshihiko Hatanaka 31 George Nakayama 51 John Farris 71 Ulo Palm 91 Stephen Ostroff 12 Tarit Mukhopadhyay 32 Jane Griffiths 52 Nigel Theobald 72 Alain Pralong 92 Arthur Levinson 13 Severin Schwan 33 Ruth McKernan 53 Pierre Chambon 73 Andrew Dillon 93 Heather Bresch 14 Vikramaditya Yadav 34 Tomasz Sablinski 54 John Talley 74 Catherine Tuleu 94 Anthony Fauci 15 David Bentley 35 Stephane Bancel 55 Jeffrey Kasher 75 Daniel Kohane 95 K. Mazumdar-Shaw 16 Richard Heyman 36 Pascal Soriot 56 Harold Varmus 76 Dennis Jenke 96 Andrew Witty 17 William G. Kaelin 37 Bernhardt Trout 57 Joerg Reinhardt 77 Craig Lipset 97 Charles Sawyers 18 Julian Morris 38 Randy Mrsny 58 Anthony Lubiniecki 78 Carl June 98 Andy Skibo 19 Manish Soman 39 Kenneth Getz 59 John Lechleiter 79 Indresh K. Srivastava 99 Wim Leereveld 20 Joseph Kim 40 Ajaz Hussain 60 Joseph Famulare 80 Joseph Jimenez 100 Francis Collins 21-100 (in reverse alphabetical order) 25

Bernhardt Trout Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, MIT and Director, Novartis-MIT Center for Continuous Manufacturing, USA

Bernhardt says, “The achievements I’m most proud of? Working with students, staff, and colleagues from MIT and worldwide, to successfully develop pharmaceutical development and manufacturing technology and to raise public awareness of the benefits of that technology to patients, and to get them medicines in a more streamlined and less expensive way.” https://novartis-mit.mit.edu

Nigel Theobald Marco Taglietti Founder and CEO, CEO, Scynexis, USA N4 Pharma, UK Marco previously served as Executive “As a serial entrepreneur and passionate Vice President, Research and Abbe Steel developer of new products, I’m now in Development and Chief Medical Officer Founder and CEO, HealthiVibe the position of owning my own drug of Forest Laboratories and President of the reformulation company with an incredibly Forest Research Institute until the company Abbe created HealthiVibe, after 25 years experienced and respected board and two was acquired by Actavis, plc. A nominator in the life sciences industry, to help pharma world class technology platforms,” says described him as an “energetic, enthusiastic, sponsors gain insight into their patients’ needs. Nigel. “This shows what can be achieved if knowledgeable, and passionate leader within “As a result, I’ve helped companies create more you stick to a focused business model!” the industry.” patient-centered trials and worked to advance www.n4pharma.co.uk www.scynexis.com a culture where the patient comes first.” http://healthivibe.com

Indresh K. Srivastava Vice President, Product Realization, Protein Sciences Lars Rebien Sørensen With a strong background in vaccine Chief Executive Officer, Novo Nordisk A/S development, particularly immunogen Revenue: DKK 88.8 billion Manish Soman design, purification, analytical and ($12.9 billion) (2014) President and CEO, Sciformix formulation development, Indresh has Employees: circa 41,500 published extensively in these areas. He In just three years, Manish helped Sciformix served on the NIH special emphasis study Lars Rebien Sørensen joined Novo to evolve from a niche area into a leading section focused on vaccine development for Nordisk’s Enzymes Marketing in 1982 and global scientific process organization for the 10 years and spent more than 12 years at in May 1994 he was appointed a member of biopharmaceutical, generic pharmaceutical, Chiron Corporation/Novartis Vaccines Corporate Management. He was appointed consumer product, medical device and contract and Diagnostics. president and CEO in November 2000. research industries. www.proteinsciences.com www.novonordisk.com www.sciformix.com